Get the Stockscreener App
1.915
4.05%
0.065
Mira Pharmaceuticals Inc stock is traded at $1.915, with a volume of 459.74K.
It is up +4.05% in the last 24 hours and up +67.39% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.85
Open:
$1.86
24h Volume:
459.74K
Relative Volume:
0.23
Market Cap:
$31.39M
Revenue:
-
Net Income/Loss:
$-12.78M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-4.71M
1W Performance:
+11.27%
1M Performance:
+67.39%
6M Performance:
+162.62%
1Y Performance:
+27.48%
1-Day Range:
$1.86
$1.9699
1-Week Range:
$1.71
$2.56
52-Week Range:
$0.51
$6.40
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials - Yahoo Finance
SoFi Stock Jumps As CEO Hails 'Strongest Quarter In Our History': Retail Confidence Grows - Barchart
What To Expect From NVIDIA's Next Quarterly Earnings Report - Barchart
What You Need To Know Ahead Of Applied Materials' Earnings Release - Barchart
Warren Buffett Loves SiriusXM, But These 2 Media Stocks Are Better Buys - Barchart
Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight In Rapidly Growing $1 Billion Market - Barchart
Teladoc (TDOC) To Report Earnings Tomorrow: Here Is What To Expect - Barchart
Multiple Conductive Anomalies Identified At Hulk - Barchart
Becton, Dickinson And Company Earnings Preview: What To Expect - Barchart
ICP DAS-BMP Introduces Latest TPU Materials to Transform Healthcare at COMPAMED 2024 - Barchart
1 'Strong Buy' Dividend Stock That Insiders Are Buying - Barchart
Wheat Posts Monday Losses - Barchart
Beyfortus® Immunization To Protect Infants From RSV Has Begun - Barchart
Weil Group Commences Helium Production From New Alberta Facility - Barchart
F5 (NASDAQ:FFIV) Surprises With Q3 Sales, Stock Soars - Barchart
CRTC approves Google's application and paves way for annual $100 million contribution to Canadian news organizations - Barchart
Transcat (NASDAQ:TRNS) Reports Sales Below Analyst Estimates In Q3 Earnings - Barchart
Tapestry, Capri File Notice To Appeal Court Decision Blocking Their $8.5 Billion Merger - Barchart
PSP Services Inc. Announces Agreement to Acquire the NCR Atleos Debit Card Production and Transaction Processing Business in Canada - Barchart
End of the 2024 cruise season: the Port of Montreal bolsters its status as a must-visit destination in North America - Barchart
AI Platform Haiper Launches Powerful 2.0 Video Model For Increased Realism And Faster Generations - Barchart
Hologic's Quarterly Earnings Preview: What You Need To Know - Barchart
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain - Yahoo Finance
YUL Passengers Now Have Access To CATSA's New CT Technology - Barchart
Canadian-led high seas mission finds illegal harvesting of shark fins and "dark vessels" in North Pacific - Barchart
Why Is MicroStrategy (MSTR) Stock Rocketing Higher Today - Barchart
Autonomix’s Stock Rallies On Strong Trial Results: Retail Sentiment Soars - Barchart
Should You Buy Microsoft Stock Before It Reports Earnings? - Barchart
What You Need To Know Ahead Of Micron Technology's Earnings Release - Barchart
3 Stocks That Goldman Sachs Expects To Beat The Market In 2025 - Barchart
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Here's What To Expect From Accenture's Next Earnings Report - Barchart
Apple, Microsoft, Google, Meta, Amazon: How’s Retail Feeling About These Big Tech Stocks Ahead Of Earnings This Week? - Barchart
CMA Calls For Elimination Of Sick Note Requirements By Employers - Barchart
Hope for Chemo Patients: New Pre-Clinical Study Shows Mira Pharmaceuticals Ketamir-2 Beats Competitors' Chemo Pain Reduction by Over 60% - Barchart
SiriusXM Canada kicks off holiday season with new Jimmy Fallon holiday channel and the return of beloved festive channels - Barchart
Ketamir-2 shows promise in preclinical pain study - Investing.com India
MAXSUN 800 SERIES MOTHERBOARD LAUNCH EVENT HELD IN BEIJING - Barchart
Soleno Therapeutics To Participate In Upcoming November Investor Conferences - Barchart
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Brazosport Facts
Ranger Energy: Q3 Earnings Snapshot - Barchart
Uranium Royalty Acquires Existing Royalty on Cameco's Advanced Stage Millennium and Cree Extension Uranium Projects - Barchart
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024 - Market Exclusive
Real Estate Sector Outperforms: 3 Stocks To Gain Exposure - Barchart
Mira Pharmaceuticals reports preclinical success with Ketamir-2 By Investing.com - Investing.com Australia
Ketamir-2 from MIRA Pharmaceuticals Raises the Bar in Pain Management, Outshining FDA-Approved Treatments - Barchart
Mira Pharmaceuticals reports preclinical success with Ketamir-2 - Investing.com India
CRTC Sets Rates That Will Allow For Greater Choice Of Internet Services - Barchart
Mega-Cap Tech Stocks To Buy For AI Growth: AMZN And META - Barchart
Newell Earnings Meet Estimates In Q3, Core Sales Decline 1.7% Y/Y - Barchart
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):